ReviewmAbs2018
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
Review in mAbs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 86 citations in OpenAlex.
- Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.BMC pulmonary medicine · 2019Trial
- Article
- Nanozymes as Emerging Therapeutics for Asthma: A Redox-Responsive and Immunomodulatory Strategy.Biomedicines · 2026Review
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- Immune cell and cytokine profiles in a murineJournal of biomedical research · 2026Article
- Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus.Journal of asthma and allergy · 2026Article
- Blood eosinophils as predictors of asthma exacerbations in adults: converging evidence from mendelian randomization, single-cell transcriptomics, and a two-center longitudinal cohort.Frontiers in immunology · 2026Article
- Application of Biologics in the Treatment of Asthma in the Past Two Decades: A Bibliometric Analysis and Beyond.Journal of asthma and allergy · 2025Review
- Type 2 asthma paediatric patients eligible for dupilumab: An Italian biomarker-based analysis.The World Allergy Organization journal · 2024Article
- Geographic and economic influences on benralizumab prescribing for severe asthma in Japan.Scientific reports · 2024Article
- Asthma Phenotypes in the Era of Personalized Medicine.Journal of clinical medicine · 2023Review
- The combination of machine learning and untargeted metabolomics identifies the lipid metabolism -related gene CH25H as a potential biomarker in asthma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- The Role and Clinical Relevance of Osteopontin in Allergic Airway Diseases.Journal of clinical medicine · 2023Review
- Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.Journal of asthma and allergy · 2023Article
- The Role ofInternational journal of molecular sciences · 2022Review
- Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms.Allergy, asthma & immunology research · 2022Review
- Severe asthma in children: An official statement from Saudi Pediatric Pulmonology Association.Saudi medical journal · 2022Article
- Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach.Frontiers in allergy · 2022Article
- Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?International journal of molecular sciences · 2021Review
- Fasting impairs type 2 helper T cell infiltration in the lung of an eosinophilic asthma mouse model.FEBS open bio · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe asthma forms, but the outcome has only been successful if the biologic, as add-on treatment, targeted specific patient subgroups. Indeed, we now realize that asthma is a heterogeneous disease with multiple phenotypes, based on distinct pathophysiological mechanisms, called endotypes. Thus, asthma therapy is gradually moving to a personalized medicine approach, tailored to individual's asthma endotypes identified through biomarkers. Here, we review the clinical efficacy of antibody-related therapeutics undergoing clinical trials, or those already approved, for the treatment of severe type 2 asthma. Biologics targeting type 2 cytokines have shown consistent efficacy, especially in patients with evidence of type 2 inflammation, suggesting that the future of asthma biologics is promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.